INVESTOR OVERVIEW
Corporate profile
Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The company’s product candidate, elraglusib is a small molecule GSK-3 inhibitor designed to restore balance in the NF-κB pathway, effectively reducing inflammation, chemoresistance, and tumor progression. Elraglusib injection is being developed as a potential monotherapy and as part of combination therapy in pancreatic cancer and Ewing sarcoma, while elraglusib oral tablet is being developed in solid cancers. The U.S. Food and Drug Administration (FDA) has granted elraglusib Fast Track and Orphan Drug designations for the treatment of pancreatic cancer.
Events
Press releases
Disclosure Channels to Disseminate Information
Actuate Therapeutics’ investors and others should note that we announce material information to the public about our company and its technologies, clinical and corporate developments, and other matters through a variety of means, including this website, press releases, SEC filings, and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public on this website and in the locations below as such information could be deemed to be material information.
- X account (formerly Twitter): @ActuateThera or https://x.com/ActuateThera
- LinkedIn: https://www.linkedin.com/company/actuate-therapeutics-inc./
- Facebook profile: https://www.facebook.com/profile.php?id=61572431561095
Investors and other interested parties can also subscribe to our social media accounts at the aforementioned addresses. Please note that this list may be updated from time to time.